Evidence map›Paper›PMID 36208028›Full record

ArticleEuropean journal of haematology2023

Phenotype of BTK-lacking myeloid cells during prolonged COVID-19 and upon convalescent plasma.

André M C Gomes, Guilherme B Farias, Amelia C Trombetta, Ana Godinho-Santos, Inês Parreira, Hélder Diogo Gonçalves, Mariana Lessa Simões, Patrício Aguiar, Maria Manuel Deveza, João Inácio and 2 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in European journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

André M C GomesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-5806-4707
Guilherme B FariasInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-9073-9401
Amelia C TrombettaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-3285-3086
Ana Godinho-SantosInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0001-8555-0789
Inês ParreiraServiço de Medicina II, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-2017-2697
Hélder Diogo GonçalvesServiço de Medicina II, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-4908-2986
Mariana Lessa SimõesServiço de Medicina I, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.ORCID https://orcid.org/0000-0001-8031-7371
Patrício AguiarServiço de Medicina I, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-2393-3463
Maria Manuel DevezaServiço de Imuno-Hemoterapia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-7967-9559
João InácioServiço de Imagiologia Geral, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-3210-3285
Ana E SousaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-4618-9799
Susana Lopes da SilvaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-3943-1185
Hospital de Santa Maria · PTUniversity of Lisbon · PT

Funding

Fundação para a Ciência e a TecnologiaJanssen Pharmaceuticals
6 · The paper itself

Abstract

XLA patient with 7-month course of COVID-19 with persistent plasma SARS-CoV-2 load revealed a sustained non-inflammatory profile of myeloid cells in association with contained severity of disease, arguing in favor of the use of BTK inhibitors in SARS-COV-2 infection.

Indexed as

COVID-19Genetic Diseases, X-LinkedAgammaglobulinaemia Tyrosine KinaseCOVID-19 SerotherapyHumansMyeloid CellsPhenotypeProtein-Tyrosine KinasesSARS-CoV-2Agammaglobulinaemia Tyrosine KinaseProtein-Tyrosine KinasesBTKCOVID-19innate immunitymonocytesSARS-CoV-2X-linked agammaglobulinemia

Identifiers

PMID36208028
PMCPMC9874515
OpenAlexW4303633860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.